N Engl J Med

Obinutuzumab shows significant clinical benefit in active lupus

March 9, 2026

In the phase 3 ALLEGORY trial (NCT04963296) involving 303 adults with active systemic lupus erythematosus (SLE; excluding lupus nephritis), obinutuzumab was associated with higher SLE Responder Index 4 (SRI-4) response rates at 52 weeks than placebo (76.7% vs. 53.5%). The therapy also outperformed placebo across all key secondary measures, including British Isles Lupus Assessment Group (BILAG)-based responses, glucocorticoid-sparing outcomes, and time to flare. While adverse events were slightly higher with obinutuzumab, serious events and mortality were comparable.

Clinical takeaway: Obinutuzumab may offer an additional option for patients with active, non‑renal SLE despite standard therapy; clinicians should monitor for infusion and infection-related adverse events.

Source:

Furie RA, et al; ALLEGORY Trial Investigators. (2026, March 6). N Engl J Med. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. https://pubmed.ncbi.nlm.nih.gov/41789864/